No Picture
Trading Ideas

Dalio Says Investors ‘Crazy’ to Hold Government Bonds Now

(Bloomberg) — Bridgewater Associates’ Ray Dalio, founder of of the world’s largest hedge fund, said investors would be “crazy” to hold government bonds now because of money printing by central banks to rescue the global economy.“This period, like the 1930-45 period, is a period in which I think you’d be pretty crazy to hold bonds,” Dalio said Wednesday on the Bloomberg Invest Talks webcast. “If you’re holding a bond that gives you no interest rate, or a negative interest rate, and they’re producing a lot of currency and you’re going to receive that, why would you hold that bond?”Dalio may …read more […]

No Picture
Trading Ideas

OPEC+ or minus? Oil supply cut numbers puzzle markets

Days after OPEC+ reached a record deal to cut oil output in an attempt to shore up a market reeling from the coronavirus crisis, their calculations are in question. The Organization of the Petroleum Exporting Countries (OPEC), along with Russia and other producing nations – known as OPEC+ – has partnered with other oil-pumping countries including the United States to cut supply by around 20 million barrels per day. “No matter how hard OPEC tries to convince the market of its strength and resolve, it has so far failed to succeed.” …read more […]

No Picture
Trading Ideas

‘The whole conversation really has to shift from war against the virus to how are we going to reopen’: Strategist on economy

Academy Securities Head of Macro Strategy Peter Tchir joins Yahoo Finance’s On The Move panel to discuss market outlook, and the potential reopening of the economy amid the coronavirus pandemic. …read more […]

No Picture
Trading Ideas

GILD: Second Covid-19 Study of Remdesivir in China Suspended; Expect Key Data in Coming Weeks

Gilead’s (GILD) remdesivir study in China for mild-moderate Covid-19 patients has just been suspended due to poor enrollment. The news comes as the pandemic continues to wane in China, and follows the recently announced termination of the study for severe Covid-19 patients for similar reasons.According to reports, the mild-moderate study had planned to enroll 308 patients from Wuhan- but it remains unclear exactly how many enrolled to date. The stock is currently down 3% in today’s trading, but is still up 16% year-to-date.For RBC Capital analyst Brian Abrahams this latest update is a worrying sign of the drug’s efficacy. He …read more […]